We identified nine novel risk proteins (RELA, ETS1, NFATC1, BATF, LCK, PIK3R1, PRKCB, RASGRP1,and FYN) as potential therapeutic targets for RA and they significantly contribute in the disease pathogenesis. Here, NFATC1 is linked to rheumatoid arthritis.